Clinical Trials Logo

HER2-Positive Solid Tumors clinical trials

View clinical trials related to HER2-Positive Solid Tumors.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06328738 Recruiting - Colorectal Cancer Clinical Trials

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Start date: June 1, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemotherapy in participants with advanced-stage HER2-positive colorectal cancer and breast cancer.

NCT ID: NCT04280341 Recruiting - Clinical trials for HER2-Positive Solid Tumors

JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors

Start date: June 3, 2020
Phase: Phase 1
Study type: Interventional

This is a non-randomized, open-label, single-arm, multicenter Phase I clinical trial which will evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of RC48-ADC in combinaton with Anti-PD1 Monoclonal Antibody in Treatment of HER2-Positive Advanced Malignant Solid Tumors.

NCT ID: NCT04278144 Recruiting - Clinical trials for HER2-positive Breast Cancer

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Start date: February 24, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies